For heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis…. ANDA 205962, held by Eugia Pharma. Bivalirudin.
As of Nov 16, 2026, ANDA 205962 (Bivalirudin), held by Eugia Pharma, was first approved by FDA on Jul 27, 2018, with 1 approved supplement and 0 published complete response letters.
Bivalirudin for injection is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Bivalirudin for injection is a direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 27, 2018 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Bivalirudin250MG/VIAL · injectable;intravenous | Bivalirudin | Discontinued |
| Sep 23, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 27, 2018 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters